AstraZeneca PLC filings document the disclosures of a foreign private issuer focused on prescription medicines across oncology, rare diseases, cardiovascular, renal and metabolism, respiratory, and immunology. The company’s Form 6-K reports include quarterly operating results, product sales, alliance and collaboration revenue, EPS measures, and management commentary on medicine performance and pipeline progress.
Other filings record FDA advisory-committee and approval updates for medicines such as TRUQAP, BREZTRI, SAPHNELO, camizestrant, and ULTOMIRIS; Phase III trial disclosures; licensing arrangements; Board changes; total voting rights; and admission of additional ordinary shares. These documents also provide capital-structure and governance information relevant to AstraZeneca’s UK issuer framework and SEC foreign-issuer reporting obligations.
AstraZeneca Finance LLC is offering three series of unsecured notes, each fully and unconditionally guaranteed by AstraZeneca PLC. The notes will bear semi-annual interest, be issued in registered book-entry form through DTC and are expected to be listed on the New York Stock Exchange.
The issuer intends to use net proceeds for general corporate purposes, which may include refinancing existing indebtedness. The notes are payable under New York law, may be redeemed (including for certain tax events), and will rank equally with other unsecured, unsubordinated indebtedness of the issuer and guarantor.
AstraZeneca PLC submitted a notice that it has included disclosures required by Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act in its Annual Report on Form 20-F for the year ended December 31, 2025. The company states the disclosure appears under "Item 4.B Business Overview—Disclosures Under the Iran Threat Reduction and Syria Human Rights Act of 2012."
AstraZeneca PLC has filed its Form 20‑F annual report for the year ended 31 December 2025, summarising its global operations, risks and product portfolio. The company lists ordinary shares and multiple long-dated notes on the New York Stock Exchange and reports 1,550,907,927 ordinary shares outstanding at year-end.
The filing incorporates by reference the detailed 2025 Annual Report, while this document highlights extensive risk factors across product development, pricing, supply chain, cybersecurity, AI, legal and sustainability areas. It presents a broad late‑stage pipeline in oncology, cardiovascular, respiratory and rare disease, with numerous Phase III trials and anticipated data readouts beyond 2026.
AstraZeneca also discloses patent expiry ranges for key marketed medicines such as Tagrisso, Imfinzi, Farxiga, Calquence, Ultomiris and others, flagging ongoing generic challenges and potential ‘at risk’ launches. Selected product sales data show Tagrisso at $7,254 million and Farxiga/Forxiga at $6,670 million in 2025, underlining oncology and CVRM as major revenue drivers.
AstraZeneca PLC has published its 2025 Annual Report and Form 20-F information. The report is available on the company’s website and will also be submitted to the UK National Storage Mechanism for public inspection. Printed copies will be sent to shareholders in due course.
The company confirmed that its Annual General Meeting will take place on 9 April 2026. The Annual Report includes key regulated information such as principal risks and uncertainties, the directors’ responsibility statement for the financial statements and directors’ report, and a statement on related party transactions.
AstraZeneca PLC reported upcoming changes to its Board of Directors. Non-Executive Director Nazneen Rahman will retire from the Board at the conclusion of the Company’s AGM on 9 April 2026, after serving since 2017 in several key committee roles.
At the same AGM, Tony Mok will become Chair of the Sustainability Committee and join the Nomination and Governance Committee, while Birgit Conix will join the Sustainability Committee. The company highlights Rahman’s contributions to science, sustainability and governance during her tenure.
AstraZeneca reports that the US Food and Drug Administration approved Calquence (acalabrutinib) plus venetoclax as the first all-oral, fixed-duration combination for adults with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma in the 1st-line setting.
The 14‑month regimen is supported by the Phase III AMPLIFY trial, where 77% of patients on Calquence plus venetoclax were progression free at three years versus 67% on standard chemoimmunotherapy, and the combo reduced the risk of disease progression or death by 35% (hazard ratio 0.65).
Median progression-free survival was not reached for the Calquence combination versus 47.6 months for chemoimmunotherapy, and safety was consistent with the known Calquence profile without new safety signals.
AstraZeneca PLC reported strong full-year 2025 results with broad-based growth. Total Revenue rose to $58,739m, up 8% at constant exchange rates, led by Oncology, BioPharmaceuticals and Rare Disease. Reported EPS increased to $6.60, up 43% at constant exchange rates, while Core EPS grew 11% to $9.16.
The company highlighted 16 positive Phase 3 readouts and 43 major approvals over the last 12 months and now counts 16 blockbuster medicines. A total dividend of $3.20 per share for 2025 was declared, up 3%, with an intended increase to $3.30 per share in 2026.
For 2026, AstraZeneca guides to mid‑to‑high single‑digit Total Revenue growth and low double‑digit Core EPS growth at constant exchange rates, with a Core tax rate of 18–22%. The company also began trading ordinary shares on the NYSE, announced $15bn of planned investment in China through 2030, and signed major pipeline and collaboration deals, including a $1.2bn upfront weight‑management portfolio agreement with CSPC and sizeable oncology transactions with Jacobio Pharma and AbelZeta.
AstraZeneca reports that the US FDA issued a complete response letter for the Biologics License Application for subcutaneous Saphnelo in adults with systemic lupus erythematosus, but the company has submitted additional information and expects an FDA decision in the first half of 2026.
The subcutaneous form is supported by the Phase III TULIP-SC trial, which met its primary endpoint of reducing disease activity with a safety profile consistent with the approved IV formulation. Subcutaneous Saphnelo is already approved in the European Union for adults with moderate to severe lupus.
Saphnelo IV is approved in more than 70 countries, and more than 40,000 patients have been treated globally. Under an updated 2025 agreement, AstraZeneca will pay Bristol-Myers Squibb a mid-teens royalty on US Saphnelo sales.
AstraZeneca PLC reports its updated share capital and voting rights position. As at 31 January 2026, the company has 1,550,944,612 ordinary shares of US$0.25 in issue, all with voting rights and none held in treasury, giving the same total number of voting rights.
This figure is provided so shareholders can use it as the denominator when calculating whether they must notify their holdings or changes in holdings under the UK Financial Conduct Authority’s Disclosure and Transparency Rules.